ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Also in this 8-page issue: John Niederhuber joins NCI as special advisor, quits NCAB. Harold Freeman steps down as NCI disparities head.

September 9, 2005

Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded

October 23, 2009

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002

House Committee Investigates ESA Safety, Urges Amgen, J&J, To Stop Promotions.

March 23, 2007

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

July 25, 2008

Plant-Based Diet Associated With Improved Survival

April 25, 2008